International Day of Older Persons: AOP Health Brings Urgent Attention to the Silent Burden of Venous Leg Ulcers Every year on October 1, the world observes the United Nations’ International…
ENHERTU® Demonstrates Significant Superiority Over T-DM1 in DESTINY-Breast05 Phase 3 Trial for High-Risk HER2 Positive Early Breast Cancer Patients Positive topline results from the planned interim analysis of the DESTINY-Breast05…
Savara Presents New Phase 3 IMPALA-2 Data on Molgramostim for Autoimmune Pulmonary Alveolar Proteinosis at ERS Congress 2025 Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company dedicated to developing therapies…
Quince Therapeutics Publishes Advanced Population PK Modeling Study of eDSP in Pediatric Ataxia-Telangiectasia Patients in CPT: Pharmacometrics & Systems Pharmacology Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company pioneering…
Lundbeck Partners with Migraine Community to Transform Care and Improve Lives Despite being recognized as one of the leading causes of disability worldwide, migraine remains widely misunderstood, and the profound…
Bayer Canada Partners with Mint Pharmaceuticals to Enhance Access to ADALAT® XL 30 mg Tablets Across the Country Bayer Canada has announced a significant new partnership with Mint Pharmaceuticals Inc.…
TAE Life Sciences and University of Wisconsin–Madison Collaborate to Bring Revolutionary Accelerator-Based BNCT Cancer Therapy to the U.S. TAE Life Sciences (TLS), a global innovator in the field of advanced…
Kardigan Accelerates Development of Transformative Cardiovascular Medicines Across Three Critical Disease Areas Kardigan, a pioneering heart health company dedicated to modernizing cardiovascular drug development, today unveiled the three late-stage clinical…
BioAlberta Celebrates Industry Leaders with Annual Achievement Awards at Health and Life Sciences Showcase Each year, Global Biotech Week and Life Sciences Week serve as a reminder of the enormous…
Indero Marks 25 Years of Innovation in Clinical Research and Looks Ahead to a New Era in Dermatology and Rheumatology Indero, the specialized contract research organization (CRO) formerly known as…
New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies Novartis today announced new data from two Kesimpta® (ofatumumab) studies in relapsing multiple…
Acadia Scraps Prader-Willi Drug After Late-Stage Failure Acadia Pharmaceuticals was testing the drug, an intranasal formulation of the oxytocin analogue carbetocin, for its potential to ease hyperphagia in the rare…